The onset of the Covid-19 pandemic in 2020 made telemedicine specialist Teladoc Health < NYSE:TDOC> famous on Wall Street. Investors are fickle, though, and in 2021 TDOC stock was unloved and, perhaps, underpriced.
In early 2022, the sentiment surrounding Teladoc is still overwhelmingly bearish. For example, Piper Sandler analyst Sean Wieland recently lowered his price target on Teladoc from $183 to $118.
